Literature DB >> 33900295

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System.

Stephen Angeloni1, Andrew Cameron2, Nicole D Pecora3, Sherry Dunbar4.   

Abstract

The COVID-19 pandemic has underscored the need for rapid high-throughput methods for sensitive and specific serological detection of infection with novel pathogens, such as SARS-CoV-2. Multiplex serological testing can be particularly useful because it can simultaneously analyze antibodies to multiple antigens that optimizes pathogen coverage, and controls for variability in the organism and the individual host response. Here we describe a SARS-CoV-2 IgG 3-plex fluorescent microsphere-based assay that can detect both IgM and IgG antibodies to three major SARS-CoV-2 antigens-the spike (S) protein, spike angiotensin-converting enzyme-2 (ACE2) receptor-binding domain (RBD), and nucleocapsid (Nc). The assay was shown to have comparable performance to a SARS-CoV-2 reference assay for IgG in serum obtained at ≥21 days from symptom onset but had higher sensitivity with samples collected at ≤5 days from symptom onset. Further, using soluble ACE2 in a neutralization assay format, inhibition of antibody binding was demonstrated for S and RBD.

Entities:  

Year:  2021        PMID: 33900295     DOI: 10.3791/62487

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  2 in total

1.  Simultaneous Measurement of IgM and IgG Antibodies to SARS-CoV-2 Spike, RBD, and Nucleocapsid Multiplexed in a Single Assay on the xMAP INTELLIFLEX DR-SE Flow Analyzer.

Authors:  Andrew Cameron; Jessica L Bohrhunter; Claire A Porterfield; Rupinder Mangat; Michael H Karasick; Zachary Pearson; Stephen Angeloni; Nicole D Pecora
Journal:  Microbiol Spectr       Date:  2022-04-07

Review 2.  Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology.

Authors:  Sundararaj Stanleyraj Jeremiah; Kei Miyakawa; Akihide Ryo
Journal:  J Mol Cell Biol       Date:  2022-08-17       Impact factor: 8.185

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.